Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.
Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Two dental companies go public inside a week, with very different results.
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.